Simulations Plus, Inc. (SLP) Stock Analysis and Metrics

Sector: Healthcare Industry: Health Information Services CIK: 0001023459

Market Cap 240.95 Mn

P/E -3.74

P/S 3.06

Div. Yield 0.00

ROIC (Qtr) -0.52

Revenue Growth (1y) (Qtr) -2.66

Add ratio to table...

About

Simulations Plus, Inc., often recognized by its stock symbol SLP, is a prominent player in the development of modeling and simulation software for drug discovery and development. This company is a global leader, delivering cost-effective software and insightful consulting services to a diverse range of industries, including pharmaceuticals, biotechnology, agrochemicals, cosmetics, and food. Their services are also utilized by academic and regulatory agencies worldwide. Simulations Plus' primary business activities revolve around the creation and...

Simulations Plus, Inc., often recognized by its stock symbol SLP, is a prominent player in the development of modeling and simulation software for drug discovery and development. This company is a global leader, delivering cost-effective software and insightful consulting services to a diverse range of industries, including pharmaceuticals, biotechnology, agrochemicals, cosmetics, and food. Their services are also utilized by academic and regulatory agencies worldwide.

Simulations Plus' primary business activities revolve around the creation and distribution of simulation software, as well as the provision of consulting services. The company's operations span various countries and regions, with a clientele that includes both private and public sector entities.

The company's revenue is primarily generated through its software business, which contributes to 61% of the total revenue. The flagship product, GastroPlus, is a mechanistically based simulation software that mimics the absorption and drug interaction of compounds administered to humans and animals. Other software products offered by the company include ADMET Predictor, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and MonolixSuite. These products cater to a wide range of needs in the drug discovery and development process.

Simulations Plus' services business, accounting for 39% of the total revenue, primarily offers consulting services. These services encompass population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. These consulting services are in high demand, as pharmaceutical companies seek scientific, therapeutic-area-related modeling expertise that they may not have in-house.

In the industry, Simulations Plus competes with several established companies that provide screening, testing, and research services, often with products not based on simulation software. The company's competitive advantages lie in its commitment to research and development, the industry-leading nature of its simulation and modeling software and related products and services, and its relationships with research and development departments of pharmaceutical companies, universities, and government agencies.

Simulations Plus' customers include companies involved in pharmaceuticals, biotechnology, agrotechnology, and cosmetics, as well as universities, hospitals, and government research organizations. The company's current customer base is highly fragmented, with no single customer accounting for more than 10% of its revenue.

Among the brand names and trade names of Simulations Plus' products and services are GastroPlus, ADMET Predictor, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and MonolixSuite. These names are synonymous with innovation and quality in the field of drug discovery and development.

Simulations Plus is committed to its people and has a culture of engagement, empowerment, and equity. The company has a diverse workforce, with over 95% of its global employees employed full-time, and more than 75% working within its life sciences software or consulting divisions. The company believes that its future success will depend, in part, on its ability to continue to attract, hire, and retain qualified personnel.

In terms of diversity, equity, and inclusion, Simulations Plus has made significant strides in recent years. Women currently comprise 48% of its workforce and 52% of its scientific staff, and the company has increased racial diversity with over 39% of its employees from minority backgrounds. The company has implemented the ADP workforce now platform to track its applicants and push job postings out to reach as many diverse applicants as possible.

Simulations Plus' commitment to its people, diversity, equity, and inclusion, and its ability to attract and retain qualified personnel will be key factors in its continued success.

Investment thesis

Bull case

Simulations Plus has moved decisively from a collection of standalone modeling tools to a fully integrated product ecosystem that spans discovery, development, clinical operations, and commercialization. The company has engineered seamless interoperability across its core engines—GastroPlus, MonolixSuite, ADMET Predictor, and QSP platforms—by leveraging a cloud‑scale S+ Cloud foundation and AI‑driven workflows. This convergence allows clients to run end‑to‑end simulations and regulatory submissions within a single environment, dramatically reducing data silos and turnaround times. As a result, the company can command higher value from each customer and create new upsell opportunities that were impossible under its fragmented product architecture.
The rollout of AI‑accelerated features has already begun to shift pricing dynamics in the company’s favor. By embedding AI capabilities into the base models, Simulations Plus can justify incremental price increases that reflect the added value of faster, more accurate predictions. Early customer feedback has been positive, suggesting that the market is willing to absorb modest premium pricing in exchange for tangible productivity gains. This willingness to pay provides a strong tailwind for future revenue growth without a corresponding surge in cost. The company’s plan to monetize AI modules in the near future further reinforces this upside.
Services revenue has grown 16% in the quarter, driven by a 42% jump in commercialization services and an 8% rise in development services. The backlog for services projects rose 18% to $20.4 million, indicating that customer demand is not only sustained but also expanding. The management narrative that services act as a leading indicator for software adoption is supported by the observation that as clients free up discretionary budgets, they often expand their internal modeling teams and purchase additional software licenses. This cyclical relationship between services and software is a reliable engine for cross‑selling and margin enhancement.
Macro‑economic conditions have begun to normalize for the biopharma sector. Tariff fears have eased, and most‑favoured‑nation pricing agreements are progressing, which has reduced cost uncertainty for clients. Concurrently, the biopharma funding environment is improving, providing sponsors with more capital to invest in early‑stage discovery tools. These favorable conditions are reflected in the “acceleration in year‑end spending” noted by the CEO, suggesting that future quarters may see a shift toward higher software spend as sponsors move from discretionary services to long‑term licenses.
From a financial health perspective, the company is well capitalized with $35.7 million in cash and short‑term investments, and it maintains a clean balance sheet with no debt. Strong free cash flow allows the firm to invest heavily in R&D and AI initiatives without compromising liquidity. The ability to fund innovation internally reduces reliance on external financing, preserving financial flexibility in an uncertain macro environment. The management guidance of 26% to 30% adjusted EBITDA margin for FY 2026 indicates that the company is on track to sustain high profitability.

Simulations Plus has moved decisively from a collection of standalone modeling tools to a fully integrated product ecosystem that spans discovery, development, clinical operations, and commercialization. The company has engineered seamless interoperability across its core engines—GastroPlus, MonolixSuite, ADMET Predictor, and QSP platforms—by leveraging a cloud‑scale S+ Cloud foundation and AI‑driven workflows. This convergence allows clients to run end‑to‑end simulations and regulatory submissions within a single environment, dramatically reducing data silos and turnaround times. As a result, the company can command higher value from each customer and create new upsell opportunities that were impossible under its fragmented product architecture.
The rollout of AI‑accelerated features has already begun to shift pricing dynamics in the company’s favor. By embedding AI capabilities into the base models, Simulations Plus can justify incremental price increases that reflect the added value of faster, more accurate predictions. Early customer feedback has been positive, suggesting that the market is willing to absorb modest premium pricing in exchange for tangible productivity gains. This willingness to pay provides a strong tailwind for future revenue growth without a corresponding surge in cost. The company’s plan to monetize AI modules in the near future further reinforces this upside.
Services revenue has grown 16% in the quarter, driven by a 42% jump in commercialization services and an 8% rise in development services. The backlog for services projects rose 18% to $20.4 million, indicating that customer demand is not only sustained but also expanding. The management narrative that services act as a leading indicator for software adoption is supported by the observation that as clients free up discretionary budgets, they often expand their internal modeling teams and purchase additional software licenses. This cyclical relationship between services and software is a reliable engine for cross‑selling and margin enhancement.
Macro‑economic conditions have begun to normalize for the biopharma sector. Tariff fears have eased, and most‑favoured‑nation pricing agreements are progressing, which has reduced cost uncertainty for clients. Concurrently, the biopharma funding environment is improving, providing sponsors with more capital to invest in early‑stage discovery tools. These favorable conditions are reflected in the “acceleration in year‑end spending” noted by the CEO, suggesting that future quarters may see a shift toward higher software spend as sponsors move from discretionary services to long‑term licenses.
From a financial health perspective, the company is well capitalized with $35.7 million in cash and short‑term investments, and it maintains a clean balance sheet with no debt. Strong free cash flow allows the firm to invest heavily in R&D and AI initiatives without compromising liquidity. The ability to fund innovation internally reduces reliance on external financing, preserving financial flexibility in an uncertain macro environment. The management guidance of 26% to 30% adjusted EBITDA margin for FY 2026 indicates that the company is on track to sustain high profitability.

Bear case

Software revenue declined 17% year‑to‑quarter, a sharp contraction that reflects weakening demand in the discovery and clinical operations segments. Discovery products represent only 15% of the software mix, and the company's most lucrative development products—GastroPlus and MonolixSuite—account for 81% of software revenue, leaving little cushion if these core offerings lose market share. A 17% decline in software highlights a vulnerability to shifts in customer budgets, especially as large pharma continues to consolidate and rationalize spend.
The company’s QSP licensing model relies heavily on perpetual therapeutic model sales, a business that is inherently lumpy and cyclical. The management response to the QSP question acknowledged that quarterly revenue is uneven due to the timing of model sales, which can lead to volatile earnings. Relying on a high‑margin but low‑frequency revenue stream exposes the company to timing risk and complicates forecasting, especially in a market where new therapeutic areas are emerging but not yet generating consistent licensing activity.
Consolidation among large pharmaceutical companies has emerged as a persistent headwind, as evidenced by the CEO’s admission that consolidation has pressured software renewals, particularly in the back half of FY 2025. Large sponsors merging or acquiring smaller entities often renegotiate or reduce their spend on modeling tools to streamline operations. This trend could accelerate, eroding the company’s high‑margin software base and forcing it to compete on price or lose customers altogether.
While services gross margin increased to 36% from 26%, the underlying cost base remains elevated due to a reorganization that shifted personnel to product development. The shift left the services organization with higher labor costs relative to billable revenue, creating pressure on margin sustainability. Additionally, services are inherently cyclical and sensitive to client budgets, meaning that a downturn in R&D spending could lead to a rapid decline in service income, which would offset software gains.
R&D expenses have climbed to 15% to 17% of revenue, a significant rise that could erode profitability if not offset by higher margin software or services. The company’s capitalized software expense—about 20% of work—will generate amortization charges that will pressure earnings in the coming periods. If the anticipated product releases fail to capture the market, the company may face a double hit from higher operating expenses and lower revenue growth.

Software revenue declined 17% year‑to‑quarter, a sharp contraction that reflects weakening demand in the discovery and clinical operations segments. Discovery products represent only 15% of the software mix, and the company's most lucrative development products—GastroPlus and MonolixSuite—account for 81% of software revenue, leaving little cushion if these core offerings lose market share. A 17% decline in software highlights a vulnerability to shifts in customer budgets, especially as large pharma continues to consolidate and rationalize spend.
The company’s QSP licensing model relies heavily on perpetual therapeutic model sales, a business that is inherently lumpy and cyclical. The management response to the QSP question acknowledged that quarterly revenue is uneven due to the timing of model sales, which can lead to volatile earnings. Relying on a high‑margin but low‑frequency revenue stream exposes the company to timing risk and complicates forecasting, especially in a market where new therapeutic areas are emerging but not yet generating consistent licensing activity.
Consolidation among large pharmaceutical companies has emerged as a persistent headwind, as evidenced by the CEO’s admission that consolidation has pressured software renewals, particularly in the back half of FY 2025. Large sponsors merging or acquiring smaller entities often renegotiate or reduce their spend on modeling tools to streamline operations. This trend could accelerate, eroding the company’s high‑margin software base and forcing it to compete on price or lose customers altogether.
While services gross margin increased to 36% from 26%, the underlying cost base remains elevated due to a reorganization that shifted personnel to product development. The shift left the services organization with higher labor costs relative to billable revenue, creating pressure on margin sustainability. Additionally, services are inherently cyclical and sensitive to client budgets, meaning that a downturn in R&D spending could lead to a rapid decline in service income, which would offset software gains.
R&D expenses have climbed to 15% to 17% of revenue, a significant rise that could erode profitability if not offset by higher margin software or services. The company’s capitalized software expense—about 20% of work—will generate amortization charges that will pressure earnings in the coming periods. If the anticipated product releases fail to capture the market, the company may face a double hit from higher operating expenses and lower revenue growth.

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEHC	GE HealthCare Technologies Inc.	33.03 Bn	15.79	1.60	10.00 Bn
2	VEEV	Veeva Systems Inc	28.29 Bn	31.07	8.85	-
3	BTSG	BrightSpring Health Services, Inc.	8.07 Bn	44.24	0.63	2.51 Bn
4	HQY	Healthequity, Inc.	7.09 Bn	33.49	5.40	0.96 Bn
5	WAY	Waystar Holding Corp.	4.55 Bn	37.14	4.14	1.47 Bn
6	DOCS	Doximity, Inc.	4.24 Bn	18.06	6.65	-
7	TXG	10x Genomics, Inc.	2.82 Bn	-63.00	4.38	-
8	PRVA	Privia Health Group, Inc.	2.60 Bn	110.89	1.23	-

Research Tools

Simulations Plus, Inc. (NASDAQ: SLP)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Research Tools

Simulations Plus, Inc. (NASDAQ: SLP)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password